clinical trial · NCT06300528

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

University of Utah →·phase2·active not recruiting·n = 1

Relapsed or Refractory B-cell Non-Hodgkin LymphomaMantle Cell LymphomaMarginal Zone LymphomaPemigatinib

brief summary

The purpose of this clinical trial is to learn if the study drug pemigatinib is effective in treating patients with relapsed or refractory B-cell non-Hodgkin lymphomas.

started

Oct 3, 2025

primary completion

Mar 16, 2026

completion

Mar 1, 2027

last updated

Jul 9, 2026

official title

PERFORM: A Phase II Study of Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol